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Most current articlePelvic floor muscle training (PFMT) in combination with conservative treatment is recom-
mended as first-line treatment for patients with fecal incontinence, although its efficacy is
unclear. We investigated whether supervised PFMT in combination with conservative treatment
is superior to attention-control massage treatment and conservative treatment in adults with
fecal incontinence.METHODS: We performed a randomized, controlled, superiority trial of patients with fecal incontinence at
a tertiary care center at a public hospital in Denmark. Ninety-eight adults with fecal inconti-
nence were randomly assigned to groups that received supervised PFMT and biofeedback plus
conservative treatment or attention-control treatment plus conservative treatment. The pri-
mary outcome was rating of symptom changes, after 16 weeks, based on scores from the Patient
Global Impression of Improvement scale. Secondary outcomes were changes in the Vaizey
incontinence score (Vaizey Score), Fecal Incontinence Severity Index, and Fecal Incontinence
Quality of Life Scale.RESULTS: In the intention-to-treat analysis, participants in the PFMT groupwere significantly more likely to
report improvement in incontinence symptoms based on Patient Global Impression of Improve-
ment scale scores (unadjusted odds ratio, 5.16; 95% CI, 2.18–12.19; P[ .0002). The PFMT group
had a larger reduction in the mean Vaizey Score (reduction, -1.83 points; 95% CI, –3.57 to –0.08;
P [ .04). There were no significant differences in condition-specific quality of life. In the per-
protocol analyses, the superiority of PFMT was increased. No adverse events were reported.CONCLUSIONS: This randomized controlled trial of adults with fecal incontinence provides support for a superior
effect of supervised PFMT in combination with conservative treatment compared with attention-
control massage treatment and conservative treatment. We found that participants who received
supervised PFMT had 5-fold higher odds of reporting improvements in fecal incontinence symp-
toms and had a larger mean reduction of incontinence severity based on the Vaizey Score
compared with attention control massage treatment. Clinicaltrials.gov no: NCT01705535.Keywords: Fecal Incontinence; Pelvic Floor Muscle Training; Biofeedback; Attention-Control Treatment; Physiotherapy;
Physical Therapy Modalities.er: EMG, electromyography; FIQL, Fecal
le; FISI, Fecal Incontinence Severity Index;
tant difference; PFMT, pelvic floor muscle
mpression of Improvement Scale; Vaizey
re.
© 2019 by the AGA Institute. Published by Elsevier, Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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What You Need to Know
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http://bit.ly/1C2wSLn.Background
Pelvic floor muscle training in combination with
conservative treatment is recommended as first-line
treatment for fecal incontinence. We performed a
randomized controlled trial to determine the effectsScan the quick response (QR) code to the left
with your mobile device to watch this article’s
video abstract and others. Don’t have a QR code
reader? Get one by searching ‘QR Scanner’ in
your mobile device’s app store.of supervised pelvic floor muscle training.
Findingspproximately 8% to 9% of the adult population is
Participants receiving supervised pelvic floor muscle
training had a 5-fold higher odds of reporting im-
provements of fecal incontinence and had a larger
mean reduction in incontinence severity than an
attention-control group.
Implication for patient care
Pelvic floor muscle training should be offered, in
combination with conservative treatment, as first-
line treatment for adults with fecal incontinence.Asuffering from fecal incontinence.1 The condition
is surrounded by taboo2,3; it can have a devastating
impact on quality of life2–4 and lead to major limitations
in daily life.3,4
Fecal incontinence often has multifactorial causes,
and the recommended first-line treatment consists of a
multimodal approach including information, fiber sup-
plements, antidiarrheal medication, laxatives, pelvic floor
muscle training (PFMT), and biofeedback training.5,6
PFMT is defined as systematic training of the pelvic
floor muscles and the external anal sphincter with the
aim of increasing muscle strength, endurance and/or
coordination.5,7 In most trials, PFMT is supplemented
with biofeedback training, in which the patient receives
feedback on a voluntary pelvic floor muscle contraction
and/or rectal filling.5–7
Evidence from randomized controlled trials
regarding the effect of PFMT for fecal incontinence is
lacking.5 A recent Cochrane systematic review5 included
20 randomized controlled trials to investigate the effi-
cacy of PFMT and/or biofeedback training for the
treatment of fecal incontinence in adults. Most of the
interventions were complex and included multiple
active elements. With the exception of 2 trials, which
evaluated vs surgery or evaluated PFMT and biofeed-
back training after surgery vs surgery alone, the
included trials compared different training modalities
and thus lacked a nontraining comparator.5 Two recent
trials published after the Cochrane review8,9 compared
the effect of PFMT and biofeedback training with a
group not receiving PFMT. However, neither of these
trials controlled for the nonspecific trial effect associ-
ated with the attention given by the health care pro-
fessional delivering the training interventions.8,9 This
nonspecific trial effect is known to exist and may result in
better outcomes for trial participants.10 To evaluate the
effect of PFMT, there is a need for a trial that uses a
comparator to control for this nonspecific trial effect
associated with the attention given by the health care
professional. The aim of the current trial was to investi-
gate if supervised PFMT in combination with conservative
treatment (mainly information) is superior to attention-
control massage treatment and conservative treatment
in adults with fecal incontinence. This possible superiority
effect was based on the primary outcome of changes in
fecal incontinence symptoms after 16 weeks of treatment
using the Patient Global Impression of Improvement Scale
(PGI-I).Methods
Trial Design
This was a randomized, controlled, superiority trial
comparing supervised PFMT with attention-control mas-
sage treatment. Both treatments were given in combina-
tion with conservative treatment. The trial is reported in
accordance with Consolidated Standards of Reporting
Trials.11,12 Reporting details can be found in the
Supplementary Materials and Methods section, if indi-
cated. The trial was preregistered with ClinicalTrials.gov
(NCT01705535), and a detailed trial protocol, including
the statistical analysis plan, was published before the data
were analyzed and the trial was unblinded.13
Participants and Setting
The trial was conducted at Copenhagen University
Hospital (Hvidovre, Denmark). From October 15, 2012,
to December 15, 2015, consecutive patients referred for
treatment of fecal incontinence at the Department of
Surgical and Medical Gastroenterology were screened for
eligibility.
Inclusion criteria were fecal incontinence for at least
6 months and a minimum age of 18 years. Exclusion
criteria were as follows: pregnancy, chronic diarrhea,
severe neurologic disorders (multiple sclerosis, Parkin-
son’s disease, spinal cord injury, major stroke, or
neuromuscular junction diseases), rectal prolapse, pre-
vious cancer surgery or radiotherapy in the lower
abdomen, inadequate Danish, cognitive impairment, and
having received more than 2 sessions of individually
supervised PFMT in the previous 12 months. The trial
was approved by the Regional Health Research Ethics
Committee (ID: H-2-2012-067) and the Danish Data
October 2019 PFMT vs Attention-Control Treatment for FI 2255Protection Agency (ID: HVH-2012-031). Written
informed consent was obtained from all participants.
Randomization and Blinding
Participants were allocated to 2 parallel groups
(supervised PFMT or attention-control massage treat-
ment) by simple randomization using a 1:1 ratio.
Randomization and allocation were managed by staff not
otherwise involved in the trial. A computer-generated
sequence of random group assignments was produced
and managed using sealed, opaque, numbered envelopes.
The primary investigator (A.U.), who was blinded to the
allocation sequence, enrolled the participants. It was not
possible to blind the participants or the physiotherapists
delivering the PFMT. Instead, we tried to blind the
participants to the trial hypothesis.14 This was attempted
by presenting the 2 treatments as equal both in the
verbal and written information given at enrolment and at
follow-up evaluation. All health care providers and
outcome assessors were instructed not to reveal the trial
hypothesis. The nurses delivering the conservative
treatment and all outcome assessors were blinded.
Interventions
Conservative treatment program. Both trial groups
received the same conservative treatment program
consisting of standard information about optimizing
bowel emptying and the use of fiber supplements and if
appropriate, information about antidiarrheal medication
(loperamide) and/or laxatives with local effect in the
rectum (glycerol). More details are provided in the
Supplementary Materials and Methods section.
Supervised pelvic floor muscle training and bio-
feedback. The PFMT intervention has been described
previously in detail.13 The protocol for the PFMT inter-
vention, including the complete training materials, is
freely available for download (https://doi.org/10.1016/
j.conctc.2017.07.006). In brief, the participants in the
PFMT group received 6 individual treatments distributed
over 16 weeks. Each treatment lasted 45 minutes and
consisted of individually supervised PFMT. The partici-
pants were taught correct pelvic floor contractions
verbally and by digital vaginal and rectal examination. At
every session, they received an examination of their
pelvic floor muscle function by digital vaginal and rectal
examination and by intra-anal electromyography (EMG)
biofeedback. They were instructed to perform an indi-
vidually tailored home training program daily. The pro-
gram progressed individually and consisted of 3 sets of
10 pelvic floor muscle contractions sustained for up to
10 seconds and 2 sets of 3 contractions sustained for up
to 30 seconds. A training diary was used to quantify
training adherence. More details are provided in the
Supplementary Materials and Methods section.
Attention-control massage treatment. To match the
attention associated with the supervised PFMT, theattention-control group received 6 individual treatments
performed over 16 weeks. Each treatment lasted 30
minutes and consisted of massage of the neck and back.
The participants were given no instructions in PFMT.
Outcome Measures
The primary outcome was improvement according to
the PGI-I after the 16 weeks of treatment.15 By using the
PGI-I, the participants rated changes in incontinence
symptoms after treatment using a 7-point scale (very
much better, much better, a little better, unchanged,
a little worse, much worse, or very much worse).15
Supporting secondary outcomes were the Vaizey
Incontinence Score (Vaizey Score),16 the Fecal Inconti-
nence Severity Index (FISI),17 and the Fecal Incontinence
Quality of Life Scale (FIQL).18 All questionnaires
were self-administered. Other secondary outcomes
were anorectal manometry (resting pressure and
maximum squeeze increment pressure), rectal capacity
measurements (sensory threshold, urge sensation, and
maximum tolerable volume), and fecal incontinence
episodes recorded via 14-day bowel diary. For more
details about the anorectal manometry and rectal
capacity measurements and for the covariates collected
at baseline, see the Supplementary Materials and
Methods section. Outcome measures were assessed at
baseline before randomization and within 14 days after
completion of the intervention (primary end point). Data
collection for the 36-month follow-up evaluation still is
ongoing and results from this long-term follow-up eval-
uation will be reported separately. Deviations from the
trial protocol and registration, together with explana-
tions, have been described elsewhere.13
Sample Size
Based on previous findings in the literature, we
hypothesized that 30% in the attention-control group19,20
and 60% in the PFMT group5,21 would achieve improve-
ment of their fecal incontinence symptoms.We consider this
difference to represent the minimum clinically important
difference (MCID). Improvement was defined as a score of
very much better, much better, or a little better at the PGI-I
(primary outcome). Based on a binomial distribution, we
needed a sample size of 84 to show this difference in treat-
ment effects between groups using a statistical power of
80% and a significance level of 5% (2-tailed). To account for
a drop-out rate of up to 16%, we included 102 participants.
Statistical Analyses
The statistical analysis plan has been described pre-
viously in full.13 The primary outcome, the PGI-I ratings
after 16 weeks of treatment, were analyzed by logistic
regression using the intention-to-treat principle. For the
primary analysis, the PGI-I outcome was dichotomized
into symptom improvement (3 upper values on the PGI-
2256 Ussing et al Clinical Gastroenterology and Hepatology Vol. 17, No. 11I) or unchanged or worsening symptoms (4 lower values
at PGI-I). Missing data for the PGI-I were imputed with a
score of unchanged in both groups.
As a sensitivity test, we conducted a multiple logistic
regression of the primary outcome. The model was
adjusted for use of fiber supplements, use of antidiarrheal
medication, stool consistency, incontinence type, pres-
ence of urinary incontinence, and confirmed sphincter
injuries as described in the statistical analysis plan. In the
review process the sex and age variables were added to
the adjusted analyses. The covariates were added one at a
time and subsequently all at once. As a goodness-of-fit,
the same variables were examined as modifiers one by
one, by adding them in interaction terms with the group
variable to the fully adjusted model.
Finally, per-protocol logistic regression analyses
were conducted following the principles outlined
earlier. These analyses included participants who had
attended at least 4 of 6 PFMT consultations, and had
documented home training on at least 70% of the
possible training days.
The FIQL, FISI, Vaizey Score, anorectal manometry
data, rectal capacity measurements, and number of fecal
incontinence episodes were analyzed using general
linear regression. The primary analyses were unadjusted.
As sensitivity analyses, we conducted adjusted analyses
adding all the covariates at once. The analyses were
conducted using the per-protocol principle as described
earlier. For the FIQL, FISI, and Vaizey Score, the analyses
also were conducted using the intention-to-treat princi-
ple. Missing values for total scores were imputed by
multiple imputation using the monotone method, except
for the bowel diary, for which we used the Markov Chain
Monte Carlo method. A total of 10 imputed data sets
were used. The imputation models included baseline
values for the missing end point value and group. All
general linear regression models were controlled for
goodness-of-fit by visual evaluation of residual plots to
check the assumptions of linearity, variance homogene-
ity, and normal distribution of the residuals.
All analyses were conducted in SAS version 9.4 (SAS
institute Inc, Cary, NC). All estimates are reported along
with 95% CIs and actual P values (2-sided). The level of
significance was set at .05. All authors had access to the
trial data and reviewed and approved thefinalmanuscript.Results
Participants, Baseline Characteristics,
and Attrition
Between October 15, 2012, and December 15, 2015,
we screened 458 patients for eligibility. In total, 98
participants were randomized, 49 to supervised PFMT
and 49 to attention-control massage treatment. The
overall patient flow including attrition can be seen in
Supplementary Figure 1. The baseline characteristics areshown in Table 1. The Participants in the PFMT group
were slightly older than the participants in the attention-
control group, with median ages of 65 and 58 years,
respectively. There were 6 men in the attention-control
group and 3 in the PFMT group.Outcomes
Primary outcome. In the PFMT group, 35 participants
(74.5%) reported improvement of their incontinence
symptoms vs 16 participants (35.5%) in the attention-
control group. The exact distribution of the participant
PGI-I ratings is shown in Table 2.
The unadjusted and adjusted results for the primary
outcome and the per-protocol analyses are shown in
Table 3. The intention-to-treat analyses showed an
unadjusted odds ratio of 5.16 (95% CI, 2.18–12.19) for
reporting improvement in the PFMT group compared
with the attention-control group (P ¼ .0002). When only
a score of very much better or much better was defined
as improvement the result still was significant, with
an unadjusted odds ratio of 2.98 (95% CI, 1.15–7.73;
P ¼ .025).
There were no signs of interaction between the
groups and any of the examined covariates.
Secondary and explorative analyses of the primary
outcome including a subgroup analysis according to
incontinence severity at baseline are shown in
Supplementary Table 1.
Secondary outcomes. The intention-to-treat analysis
of the Vaizey Score showed that the PFMT group had
a statistically significantly larger mean reduction in
incontinence severity than the attention-control group,
the unadjusted mean difference in change being -1.83
points (95% CI, -3.57 to -0.08; P ¼ .04) (Table 4). There
were no statistically significant differences between
groups in condition-specific quality of life or in inconti-
nence severity measured with FISI (Table 4). The
per-protocol analysis showed statistically significant
differences in favor of PFMT both for the Vaizey Score
and the 2 FIQL subscales of Lifestyle and Coping/
behavior (Table 4).
There were no significant differences in change
between groups in the anorectal manometry measure-
ments, the rectal capacity measurements, or in the
number of fecal incontinence episodes as recorded in
the 14-day bowel diary (Supplementary Table 2).
The median number of consultations was 5 (range,
0–6) in both groups. The PFMT group documented a
median of 95 home training days (range, 0–112 d) in the
training diaries, corresponding to 84.8% of the possible
training days. In the PFMT group, 43 (87.8%) attended
at least 4 of the 6 consultations, and 33 (67.4%) docu-
mented home training on at least 70% of the possible
training days. These 33 participants were included in
the per-protocol analyses. No adverse events were
reported.
Table 1. Baseline Characteristics
Variable PFMT (n ¼ 49) Attention-control (n ¼ 49)
Demographics
Age, y, median (range) 65.13 (34.30–77.29) 58.43 (26.80–89.23)
Women 46 (93.9%) 43 (87.8%)
Ethnicity, North Europe 46 (93.9%) 47 (95.9%)
Body mass index, kg/m2, median (range) 24.5 (17.3–36.1) 23.2 (18.3–47.6)
Incontinence history
Duration of fecal incontinence, y, median (range) 3.25 (0.67–50) 4.0 (0.75–24)
Stool consistency
Loose/mushy 19 (38.8%) 14 (28.6%)
Soft, but formed 11 (22.5%) 13 (26.5%)
Hard, firm 3 (6.1%) 1 (2.0%)
Varying 16 (32.7%) 21 (42.9%)
Incontinence type
Passive 10 (20.8%) 16 (33.3%)
Urgency 18 (37.5%) 14 (29.2%)
Mixed, both 20 (41.7%) 18 (37.5%)
Use of medication/fiber
Fiber supplements 24 (49%) 22 (44.9%)
Antidiarrheal medication 4 (8.2%) 5 (10.2%)
Laxatives 5 (10.2%) 7 (14.3%)
Medical history
Previous urogynecological surgery 30 (61.2%) 21 (43.8%)
Previous anal surgery 16 (33.3%) 21 (43.8%)
Presence of urinary incontinence 27 (55.1%) 24 (49%)
Diabetes mellitus 2 (4.1%) 4 (8.2%)
Inflammatory bowel diseases 2 (4.1%) 4 (8.2%)
Other diseases 21 (43.8%) 27 (55.1%)
Obstetric history
Number of women who delivered 44 (95.7%) 36 (83.7%)
Parity among women, median (range) 2 (0–4) 2 (0–4)
Self-reported questionnaires
Vaizey Score, median (range) 14 (6–22) 14 (2–20)
FISI, median (range) 27 (8–57) 28 (8–50)
FIQL Lifestyle, median (range) 3.40 (1.20–4.00) 3.20 (1.46–4.00)
FIQL Coping/behavior, median (range) 2.00 (1.11–4.00) 2.00 (1.00–4.00)
FIQL Depression/self-perception, median (range) 3.19 (1.43–3.81) 2.91 (1.48–3.81)
FIQL Embarrassment, median (range) 2.33 (1.00–3.67) 2.33 (1.00–3.67)
14-day bowel dairy
Number of fecal incontinence episodes, median (range) 2.0 (0–23) 1.5 (0–32)
Anorectal manometry
Resting pressure, mm Hg, median (range) 67.6 (38.6–124.0) 72.2 (34.4–163.5)
Maximum squeeze increment pressure, mm Hg, median (range) 109.6 (49.2–216.3) 124.4 (55.6–256.30)
Rectal capacity measurements
First sensation, mL, median (range) 30 (10–60) 20 (10–90)
Urge sensation, mL, median (range) 60 (20–180) 50 (20–170)
Maximum tolerable volume, mL, median (range) 110 (40–350) 100 (30–400)
Endoanal ultrasound, assessed at 16 weeks
Anal sphincter injuries 19 (38.8%) 14 (30.4%)
Defect <120 8 (42.1%) 2 (14.3%)
Defect 120 11 (57.9%) 12 (85.7%)
NOTE. Values are numbers (percentages) unless stated otherwise.
FIQL, Fecal Incontinence Quality of Life Scale (range, 1–4); FISI, Fecal Incontinence Severity Index (range, 0–61); PFMT, pelvic floor muscle training; Vaizey Score,
Vaizey Incontinence Score (range, 0–24).
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After 16 weeks of treatment, the participants in the
PFMT group had 5.16 times higher odds of reporting
improvement of incontinence symptoms compared with
the attention-control group.
Two other trials have reported results comparable
with our results.9,19 Damon et al9 reported an oddsratio of 2.34 for successful improvement after PFMT
and biofeedback in combination with conservative
treatment. However, in contrast to our findings, this
was not reflected in reduced severity. This may be
explained by different severity measures. Heymen
et al19 showed symptom relief for 76% after supervised
PFMT and sensitivity biofeedback vs 41% in a non-
supervised PFMT group. This was accompanied by a
Table 2. Number and Percentages of the PGI-I Ratings in the
2 Groups
PGI-I ratings
PFMT
(n ¼ 47),
frequency (%)
Attention-control
(n ¼ 45),
frequency (%)
Very much better 5 (10.6) 2 (4.4)
Much better 13 (27.7) 6 (13.3)
A little better 17 (36.2) 8 (17.8)
Improvementa 35 (74.5) 16 (35.6)
Unchanged 12 (25.5) 26 (57.8)
A little worse 0 (0) 1 (2.2)
Much worse 0 (0) 2 (4.4)
Very much worse 0 (0) 0 (0)
Unchanged or deteriorationa 12 (25.5) 29 (64.4)
Total n ¼ 47 (100) n ¼ 45 (100)
PFMT, pelvic floor muscle training; PGI-I, Patient Global Impression of
Improvement Scale.
aBoldface shows PGI-I scores were dichotomized as follows: improvement: a
score of very much better, much better, or a little better; unchanged/deterio-
ration: a score of unchanged, a little worse, much worse, or very much worse.
Across all 6 cut-off points on the PGI-I scale, the PFMT group had significantly
higher odds for reporting their symptom change in a higher/better category
than the attention-control group (P ¼ .0003).
2258 Ussing et al Clinical Gastroenterology and Hepatology Vol. 17, No. 11significant reduction in the FISI. In contrast, we were
not able to show significant changes in severity on the
FISI, but all mean between-group differences in the FISI
score, however, were in favor of PFMT and greater than
the MCID of -3.56.22
Contrary to our findings, Norton et al20 did not show
additional benefit from offering PFMT and/or biofeed-
back to conservative treatment. This may be explained
by the fact that the conservative treatment contained an
urge-resistance program with instructions of resistance
to fecal urgency by holding sustained sphincter con-
tractions for progressively longer time durations (up to
10 minutes). Whether these contractions for urge-
resistance differ from voluntary pelvic floor muscle
contractions and whether the control group reflected a
true control group could be questioned. The conclusions
of Norton et al20 of no additional benefit from PFMT
could be subject for discussion.Table 3. Primary Outcome: Odds Ratios for Reporting Improve
Treatment
ITT analysis,
unadjusted
(n ¼ 98)a
ITT analysis,
adjustedb
(n ¼ 92)c
OR (95% CI) 5.16 (2.18–12.19) 7.26 (2.55–20.69
P value .0002 .0002
NOTE. PGI-I scores were dichotomized as participants reporting either improveme
a little better) or unchanged/deterioration (a score of unchanged, a little worse, m
ITT, intention-to-treat; OR, odds ratio; PFMT, pelvic floor muscle training; PGI-I,
aImputed 6 values for missing PGI-I values.
bAdjusted for age, sex, antidiarrheal medication at baseline, fiber supplements at b
and anal sphincter injuries (at 16-week follow-up evaluation).
cNo imputations were made because of simultaneous missing values for both ou
dImputed 4 values for missing PGI-I values.Sjödahl et al8 did not showan effect of supervised PFMT
in combination with strength biofeedback compared with
conservative treatment. This result could be owing to small
sample size, minimal supervision, and/or the chosen
outcome measures (bowel diary and anorectal manom-
etry). When PFMT and conservative treatment were given
in combination, the trial showed a significant reduction in
incontinence episodes from baseline.
In the current trial, the mean between-group differ-
ences in changes on the Vaizey Score were between -1.83
and -2.24 points, this is comparable with results
reported by other investigators20,23–25 and may repre-
sent the MCID.23,24,26
Similar to other investigators,9,19 we were not able to
show the effect of PFMT on the FIQL in the intention-to-
treat analysis. We found a significant effect on the
Lifestyle and Coping/behavior subscales only in the per-
protocol analyses. Our sample size was calculated in
relation to the primary outcome and it is possible that
we did not have enough power to show significant dif-
ferences on the FIQL.
In the current trial, more than one third of patients
had sphincter injuries confirmed at endoanal ultrasound,
this reflects the tertiary setting of our trial. However, our
results may be highly relevant in a primary setting
because there is an unmet need for treatment of fecal
incontinence in primary health care,27 and the in-
terventions do not necessarily need to be conducted at
specialized centers.27 The number of sphincter injuries
may have contributed to the fact that we were not able to
show any significant differences at the anorectal
manometry. Another reason could be that the median
baseline resting and maximum squeeze pressure in the
current trial were comparable with the median for
healthy controls measured with comparable equip-
ment.28 Similar to the current trial, 2 other trials found
no significant increase in squeeze pressure after PFMT
and conservative treatment,8,24 whereas most other tri-
als have found that PFMT improved maximum squeeze
pressure.19–21,29,30 However, improvement in squeeze
pressure is not always correlated with improvement inment on the PGI-I in the PFMT Group After 16 Weeks of
Per-protocol
analysis, unadjusted
(n ¼ 82)d
Per-protocol
analysis, adjustedb
(n ¼ 78)c
) 7.66 (2.75–21.38) 7.97 (2.39–26.55)
.0001 .0007
nt of their incontinence symptoms (a score of very much better, much better, or
uch worse, or very much worse).
Patient Global Impression of Improvement Scale.
aseline, incontinence type, presence of urinary incontinence, stool consistency,
tcome and covariates.
Table 4. Supportive Outcomes
Change from baseline to follow-up
evaluation, mean change (SD)
16-week follow-up evaluation
Mean between-group difference in change from baseline to follow-up
evaluation, mean difference (95% CI), P value
ITT analyses Per-protocol analyses
Outcomes PFMT (n ¼ 47)a Attention-control (n ¼ 45)a Unadjusted (n ¼ 98)b Adjustedc (n ¼ 92)d Unadjusted (n ¼ 82)e Adjustedc (n ¼ 78)d
Vaizey Score range, 0–24 2.57 (4.51) 0.67 (4.05) 1.83 (3.57 to 0.082),
.040
1.87 (3.88 to 0.13),
.067
2.08 (4.09 to 0.07),
.042
2.24 (4.57 to 0.097),
.060
FISI range, 0–61 4.23 (10.86) 0.40 (13.05) 3.80 (8.65 to 1.061),
.13
4.64 (10.029 to 0.76),
.092
5.12 (10.61 to 0.37),
.067
5.88 (12.16 to 0.40),
.067
FIQL
Lifestyle 0.16 (0.48) 0.031 (0.50) 0.19 (0.0068 to 0.38),
.059
0.18 (0.033 to 0.40),
.010
0.22 (0.011–0.44),
.040
0.24 (0.0017 to 0.49),
.052
Coping/behavior 0.20 (0.59) 0.073 (0.43) 0.12 (0.084 to 0.33),
.24
0.08 (0.15 to 0.31),
.48
0.23 (0.01–0.45),
.037
0.18 (0.059 to 0.43),
.14
Depression/self-perception 0.017 (0.46) 0.014 (0.48) 0.031 (0.22 to 0.16),
.75
0.086 (0.30 to 0.13),
.43
0.022 (0.18 to 0.22),
.83
0.016 (0.25 to 0.22),
.90
Embarrassment 0.19 (0.80) 0.19 (0.66) 0.0056 (0.30 to 0.29),
.97
0.042 (0.29 to 0.37),
.80
0.14 (0.17 to 0.45),
.38
0.095 (0.27 to 0.46),
.61
FIQL, Fecal Incontinence Quality of Life Scale (a condition-specific quality-of-life scale consisting of 4 subscales: Lifestyle, Coping/behavior, Depression/self-perception, and Embarrassment; subscales range from 1–4, with
1 ¼ worst quality of life, 4 ¼ best quality of life); FISI, Fecal Incontinence Severity Index (with 0 ¼ complete continence, 61 ¼ complete incontinence); ITT, intention-to-treat; PFMT, pelvic floor muscle training; Vaizey Score,
Vaizey Incontinence Score (with 0 ¼ complete continence, 24 ¼ complete incontinence).
aNo imputations.
bImputed 6 values for missing end point values for each of the secondary outcomes.
cAdjusted for age, sex, antidiarrheal medication at baseline, fiber supplements at baseline, incontinence type, presence of urinary incontinence, stool consistency, and anal sphincter injuries (at 16-week follow-up evaluation).
dNo imputations were made because of simultaneous missing values for both outcome and covariates.
eImputed 4 values for missing end point values for each of the secondary outcomes.
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2260 Ussing et al Clinical Gastroenterology and Hepatology Vol. 17, No. 11clinical outcomes.21,30 It is not surprising that we did not
find any changes in the rectal capacity measurement
because EMG biofeedback is not expected to change
sensory thresholds, as one would expect from, for
example, sensitivity biofeedback.
We were not able to show any differences between
groups in the number of fecal incontinence episodes. We
had much missing data in the bowel diaries and we can
only guess what the result would have been if the data
had been more complete. Electronic assessment of in-
continence episodes could be a way to reduce the
amount of missing data in future trials.
In our trial all outcome assessors and researchers
were blinded, and we did try to blind the participants to
the trial hypothesis. It was not possible to blind the
participants or the physiotherapists to the treatment
allocation. The lack of blinding may have resulted in a
higher placebo response in the PFMT group14 owing to
higher expectations of treatment effect. We did not
measure to what extent the participants believed that
they were receiving effective treatment, so we cannot tell
if differences in expectations between groups influenced
the subjective outcomes. However, all primary and sec-
ondary results were in favor of supervised PFMT, which
makes it less possible that our findings should be owing
solely to higher expectations in the PFMT group.
The attention-control massage treatment was chosen
as a physiologically inactive control treatment to control
for the nonspecific trial effect10 related to the attention
given by the health care professional. We could have
chosen a sham training intervention instead, but given
the fact that many patients are unable to conduct a
correct pelvic floor muscle contraction, we found it un-
ethical to teach the participants sham contractions with
the risk of rehearsing a wrong contraction that may be
difficult to correct later.
Conclusions
This trial provides support for a superior effect of
supervised PFMT in combination with conservative
treatment compared with attention-control massage
treatment and conservative treatment in adults with
fecal incontinence. Participants in the PFMT group had a
5-fold higher odds of reporting improvements in fecal
incontinence symptoms and had a larger mean reduction
of incontinence severity at the Vaizey Score. Based on the
results, PFMT in combination with conservative treat-
ment should be offered as first-line treatment for adults
with fecal incontinence.
Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
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Detailed Description of the Conservative
Treatment Program
Both trial groups received a conservative treatment
program consisting of standard information about opti-
mizing bowel emptying and the use of fiber supplements
and, if appropriate, information about the use of antidi-
arrheal medication (loperamide) and/or laxatives with a
local effect in the rectum (glycerol).
Participants were informed about regulation of stool
consistency, and following a healthy and varying the diet
with regular meals and high-fiber content was recom-
mended. In addition, they were recommended fiber
supplements such as psyllium. Psyllium was recom-
mended as a powder or capsules. Participants were
recommended to have 2 teaspoons of powder (3 g) or 6
capsules (3 g), both to be consumed twice a day. As an
alternative to or supplement to psyllium, participants
were informed that they could have a breakfast cereal
with high-fiber content. They were recommended to
drink 2.5 L liquid every day. Participants were informed
that if they were bothered by thin stool, they could use
antidiarrheal medicine (loperamide). They were recom-
mended to start with half a tablet (equaling 1 mg) and
then increase the dose until their stool was formed and
they avoided accidents, but did not become constipated.
Participants were informed that they may achieve more
complete bowel emptying by using a laxative with a local
effect in the rectum such as glycerol. They were informed
that suppositories can be used to achieve more complete
emptying after a spontaneous bowel movement or to
initiate a bowel movement.
The information in the conservative treatment pro-
gram was delivered by 1 of 3 nurses who was specialized
in fecal incontinence and was initiated on the first visit to
the outpatient clinic at the Department of Surgical and
Medical Gastroenterology before inclusion in the trial. The
information was followed up by a telephone call from
the nurse after approximately 1 month, thus the conser-
vative treatment in both groups was continued parallel to
the allocated intervention after the randomization.
In addition to the conservative treatment program,
the participants in both groups received their allocated
interventions within 14 days of their randomization. The
interventions in both groups were delivered as individ-
ual face-to-face visits at the Department of Physiotherapy
and Occupational Therapy and were distributed over 16
weeks, with treatment offered in treatment weeks 0, 2, 5,
8, 12, and 16 (1 week).Detailed Description of the Supervised Pelvic
Floor Muscle Training Intervention
Participants in the PFMT group received 6 individual
treatments of 45 minutes consisting of individuallysupervised PFMT. The treatments were given by 1 of 2
physiotherapists who was specialized in treatment of
fecal incontinence. The participants were taught correct
pelvic floor contractions verbally and by digital vaginal
and rectal examination. The verbal instruction was
“squeeze around the anus as if you were about to hold
back air or stool passing from the bowel.” At every ses-
sion, the participant received an examination of their
pelvic floor muscle function by digital vaginal and rectal
examination and by intra-anal EMG biofeedback. The
EMG biofeedback was used to give the participants vi-
sual and auditory feedback on a voluntary contraction
to enhance awareness, strength, and endurance of a
voluntary contraction and to support the performance
of correct pelvic floor muscle contractions in different
body positions and during movements. The participants
were instructed to perform an individually tailored
daily home training program. The program consisted of
3 sets of 10 pelvic floor muscle contractions sustained
for up to 10 seconds, and 2 sets of 3 contractions
sustained for up to 30 seconds. The participants also
were taught to contract the pelvic floor muscle in
response to fecal urgency and in situations with
increased abdominal pressure. A training diary was
used as a motivational tool and to quantify training
adherence. Progressive overload was achieved by
increasing the duration of the contractions and by
performing the exercises against gravity in different
body positions and during movements. The PFMT
intervention was standardized in a protocol, and pro-
tocol adherence was recorded by the physiotherapists
filling in case report forms.
Detailed Description of the Anorectal
Manometry, Rectal Capacity Measurements,
and Endoanal Ultrasonography
Anorectal manometry. The investigation was con-
ducted with the water-perfused catheter technique.
Resting pressure and maximum squeeze increment
pressure were determined. Both measures were recor-
ded in the high-pressure zone using the pull-through
technique. Maximum squeeze increment pressure was
measured as the average of 3 squeezes using the pull-
through technique (1 mm/s).
Rectal capacity measurements. A catheter was inser-
ted into the rectum and then slowly inflated with air. The
sensory threshold was determined as the minimum
volume of filling at which a rectal sensation was
perceived. Urge sensation was determined as the volume
associated with the initial urge to defecate, and the
maximum tolerated volume was determined as the vol-
ume at which the participants felt a strong desire to
defecate and felt pain or discomfort.
Anorectal manometry and rectal capacity measure-
ments were measured by a trained nurse with more
than 10 years of experience in conducting these
investigations.
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at Baseline
In addition to the outcome measures, the baseline data
consisted of demographic background information, a
medical history with an emphasis on the history of fecal
incontinence, and known risk factors for fecal incontinence,
and for women an obstetric history as well. An endoanal
ultrasonography also was conducted (at 16 weeks) to
detect internal and/or external anal sphincter defects.
Defects were defined as a gap in the muscle ring or a loss
of muscle substance in a range of more than 60. The
extension of sphincter defect was measured in degrees.Results
Secondary Analyses of the Primary Outcome
An intention-to-treat proportional odds model was
fitted with the PGI-I scores as outcome using all 7
categories.Supplementary Table 1.Odds Ratios for Reporting Improveme
Treatment by Severity Subgroups
ITT analysis, unadjusted
Incontinence seve
Subgroup 1, Vaizey Score
between 1 and 8
OR (95% CI) 1.2 (0.12–11.87)
P value n .88 n ¼ 15a
NOTE. PGI-I scores were dichotomized as participants reporting either improveme
a little better) or unchanged/deterioration (a score of unchanged, a little worse, m
ITT, intention-to-treat; OR, odds ratio; PFMT, pelvic floor muscle training; PGI-I,
Score.
aImputed 1 value for a missing PGI-I value.
bImputed 4 values for missing PGI-I values.The model showed that the participants in the PFMT
group had 4.45 times higher odds (95% CI, 2.02–9.78)
for rating their symptom changes in a higher (better)
PGI-I category across all 6 cut-off points of the PGI-I scale
(P ¼ .0002.)
During the review process, it was suggested to conduct
a subgroup analysis of the effect at the PGI-I according to
incontinence severity. We did this by dividing the partic-
ipants into 3 subgroups according to the Vaizey Score at
baseline (Vaizey Score subgroups: 1–8, 9–16, and 17–24).
The subgroup effect was examined in an intention-to-treat
logistic regression model in which the severity variable
was added as an interaction term with the group variable.
The model was unadjusted because the trial was not
powered to conduct an adjusted subgroup analyses. The
analysis showed significant interaction between baseline
severity and group (P ¼ .0076). There was no significant
effect for the group with the lowest severity at baseline
(subgroup 1), whereas both subgroups 2 and 3 had a
significant effect of supervised PFMT. The effect was most
pronounced for the group with the highest severity
(subgroup 3) (Supplementary Table 1).nt on the PGI-I in the PFMT Group After 16 Weeks of
rity at baseline measured with the Vaizey Score
Subgroup 2, Vaizey Score
between 9 and 16
Subgroup 3, Vaizey Score
between 17 and 24
6.9 (2.16–22.098) 14.4 (1.38–150.81)
.0011 n ¼ 60b .026 n ¼ 23a
nt of their incontinence symptoms (a score of very much better, much better, or
uch worse, or very much worse).
Patient Global Impression of improvement; Vaizey Score, Vaizey Incontinence
Supplementary Table 2. Explorative Outcomes
Change from baseline to
follow-up evaluation
16-week follow-up evaluation
Mean between group difference in change from
baseline to follow-up evaluation
Per protocola
Per-protocol analyses,
unadjusted (n ¼ 82)b
Per-protocol analyses,
adjustedc (n ¼ 78)d
PFMT
(n ¼ 33)
Attention-control
(n ¼ 46)
Mean change
(SD)
Mean change
(SD)
Mean difference in
change (95% CI)
P
value
Mean difference in
change (95% CI)
P
value
Anorectal manometry
Resting pressure, mm Hg 4.49 (14.38) 3.21 (18.55) 7.07 (14.75 to 0.60) .07 7.06 (15.69 to 1.58) .11
Maximum squeeze increment
pressure, mm Hg
0.72 (23.00) 1.90 (24.53) 1.77 (12.55 to 9.004) .75 3.16 (8.07 to 14.39) .58
Rectal capacity measurements
Sensory threshold, mL 1.82 (17.22) 1.96 (14.39) 0.10 (7.10 to 6.89) .98 1.14 (6.75 to 9.025) .77
Urge sensation, mL 3.33 (22.59) 4.13 (25.70) 0.32 (10.55 to 11.19) .95 0.67 (12.97 to 11.63) .91
Maximum tolerated volume, mL 9.70 (46.53) 9.78 (37.86) 0.19 (18.19 to 18.56) .98 5.77 (26.13 to 14.59) .57
14-day bowel diary
Fecal incontinence episodes 0.65 (3.87)
n ¼ 17
0.15 (4.91)
n ¼ 27
Multiple imputation 0.70 (2.99 to 4.40)
(n ¼ 82)
.71 1.12 (2.97 to 5.21)
(n ¼ 78)
.59
Imputation with zero 0.15 (2.53 to 2.22)
(n ¼ 79)e
.90 0.71 (3.66 to 2.25)
(n ¼ 75)f
.63
Complete case 0.80 (3.63 to 2.044)
(n ¼ 44)
.57 1.73 (5.08 to 1.63)
(n ¼ 43)
.30
NOTE. As described in the statistical analysis plan,13 we conducted a sensitivity analysis for the bowel diary because the missing data exceeded 10% (only 44 of
the 82 participants in the per-protocol analysis had complete outcomes for fecal incontinence episodes). In this analysis, missing values for incontinence episodes
were imputed with a value of zero because missing values predominantly were judged not to be missing at random but seemed to be negative answers. As an
extra analysis, we conducted a per-protocol analysis without imputations, only including the 44 participants with complete outcomes. This complete case analysis
was not prespecified but included because of the large amount of missing data. For the same reason, we did not analyze the number of stools recorded in the
bowel diary, as had been prespecified.
aNo imputations.
bImputed 3 values.
cAdjusted for age, sex, antidiarrheal medication at baseline, fiber supplements at baseline, incontinence type, presence of urinary incontinence, stool consistency,
and anal sphincter injuries (at 16-week follow-up evaluation).
dNo imputations were made because of simultaneous missing values for both outcome and covariates.
eImputed 35 values, missing values were imputed with zero.
fImputed 32 values, missing values were imputed with zero. The results from the 14-day bowel diary should be interpreted with great caution because of the large
amount of missing data.
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Supplementary Figure 1. Flow diagram describing patient flow through each stage of the trial. We screened 458 patients for
eligibility, of whom 45 did not meet the inclusion criteria. Among those who met the inclusion criteria, 145 were excluded
because of the presence of exclusion criteria and 166 declined participation. The main reasons for declining were long dis-
tance to the hospital or unwillingness to attend the required 9 appointments. A total of 102 participants signed the informed
consent form, but 4 dropped out before randomization. Thus, 98 participants were randomized, 49 to supervised PFMT and 49
to attention-control massage treatment. Of the 98 randomized participants, 93 were seen at the 16-week follow-up evaluation
and the primary end point was assessed in 92 participants (93.9%), except for the anorectal manometry and rectal capacity
measurements, which were measured in 93 participants. Thus, end point data for the PGI-I, the Vaizey Score, the FISI, and the
FIQL were missing for 6 participants (6.1%). ITT, intention-to-treat; PFMT, pelvic floor muscle training; PGI-I, Patient Global
Impression of Improvement Scale.
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